Edesa Biotech Files 2024 10-K, Outlines Future Milestones

TL;DR

EDSA 10-K filed. Lots of dates in the future, check for debt/equity moves.

AI Summary

Edesa Biotech, Inc. filed its 10-K for the fiscal year ending September 30, 2024. The company, formerly known as Stellar Biotechnologies, Inc., reported on its business operations and financial condition. Key dates mentioned include October 31, 2033, for a potential debt maturity and March 31, 2025, for several other financial and operational milestones.

Why It Matters

This filing provides investors with a comprehensive overview of Edesa Biotech's financial health and strategic direction for the past fiscal year, influencing investment decisions.

Risk Assessment

Risk Level: medium — Biotech companies often carry higher risk due to the nature of drug development and regulatory hurdles, and this filing details their financial standing and future obligations.

Key Players & Entities

• Edesa Biotech, Inc. (company) — Filer of the 10-K
• Stellar Biotechnologies, Inc. (company) — Former name of Edesa Biotech, Inc.
• September 30, 2024 (date) — Fiscal year end for the 10-K report
• October 31, 2033 (date) — Potential debt maturity date
• March 31, 2025 (date) — Multiple financial and operational milestone dates

FAQ

Key Financial Figures

• $37 million — nical-stage drug candidates, more than C$37 million in competitive government grant and fun
• $100,000 — verage, at an average cost of more than $100,000 per patient. 5 For moderate to severe
• $23 million — e Government of Canada committed up to C$23 million in partially repayable funding toward (
• $5.75 million — e C$23 million committed by SIF, up to C$5.75 million is not repayable. The remaining C$17.25
• $17.25 million — illion is not repayable. The remaining C$17.25 million is conditionally repayable starting in
• $14.1 million — t), the Government of Canada committed C$14.1 million in nonrepayable funding for an internat

Filing Documents

• edsa20240930_10k.htm (10-K) — 1748KB
• ex_755936.htm (EX-3.7) — 2KB
• ex_755937.htm (EX-4.11) — 27KB
• ex_755571.htm (EX-19.1) — 84KB
• ex_754891.htm (EX-23.1) — 4KB
• ex_754102.htm (EX-31.1) — 12KB
• ex_754103.htm (EX-31.2) — 12KB
• ex_754104.htm (EX-32.1) — 5KB
• ex_754105.htm (EX-32.2) — 5KB
• exh37_01.jpg (GRAPHIC) — 141KB
• exh37_02.jpg (GRAPHIC) — 141KB
• exh37_03.jpg (GRAPHIC) — 94KB
• footer2.jpg (GRAPHIC) — 7KB
• footerv1.jpg (GRAPHIC) — 5KB
• footerv2.jpg (GRAPHIC) — 4KB
• logosmall.jpg (GRAPHIC) — 3KB
• mnplogo.jpg (GRAPHIC) — 4KB
• 0001171843-24-006946.txt ( ) — 8208KB
• edsa-20240930.xsd (EX-101.SCH) — 66KB
• edsa-20240930_def.xml (EX-101.DEF) — 482KB
• edsa-20240930_lab.xml (EX-101.LAB) — 413KB
• edsa-20240930_pre.xml (EX-101.PRE) — 516KB
• edsa-20240930_cal.xml (EX-101.CAL) — 44KB
• edsa20240930_10k_htm.xml (XML) — 981KB

Risk Factors

Risk Factors 22 1B. Unresolved Staff Comments 41 1C. Cybersecurity 41 2.

Properties

Properties 42 3.

Legal Proceedings

Legal Proceedings 42 4. Mine Safety Disclosures 42 PART II 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 43 6. [Reserved] 43 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 43 7A.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 49 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 49 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 49 9A.

Controls and Procedures

Controls and Procedures 49 9B. Other Information 50 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 50 PART III 10. Directors, Executive Officers and Corporate Governance 51 11.

Executive Compensation

Executive Compensation 54 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 63 13. Certain Relationships and Related Transactions, and Director Independence 65 14. Principal Accounting Fees and Services 66 PART IV 15. Exhibits and Financial Statement Schedules 67 16. Form 10-K Summary 72

FORWARD-LOOKING STATEMENTS AND OTHER MATTERS

FORWARD-LOOKING STATEMENTS AND OTHER MATTERS This Annual Report on Form 10-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act) and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act) and, as such, may involve known and unknown risks, uncertainties and assumptions. Forward-looking statements are based upon our current expectations, speak only as of the date hereof, are subject to change and include statements about, among other things: the status, progress and results of our clinical programs; our ability to obtain regulatory approvals for or successfully commercialize any of our product candidates; our business plans, strategies and objectives, including plans to pursue collaboration, licensing or other similar arrangements or transactions; our expectations regarding our liquidity and performance, including our expense levels, sources of capital and ability to maintain our operations; the competitive landscape of our industry; and general market, economic and political conditions. Forward-looking statements are those that predict or describe future events or trends and that do not relate solely to historical matters. You can generally identify forward-looking statements as those statements containing the words "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," "continue" or other similar expressions. You should not rely on our forward-looking statements as they are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate because the matters they describe are subject to assumptions, known and unknown risks, uncertainties and other unpredictable factors, many of which are beyond our control. Our actual results could differ materially and adversely from those expressed in any forward-looking statements a

BUSINESS

Item 1. BUSINESS. Overview We are a biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our approach is to acquire, develop and commercialize drug candidates based on mechanisms of action that have demonstrated proof-of-concept in human subjects. We prioritize our efforts on disease indications where there is compelling scientific rationale, no approved therapies or where there are unmet medical needs, and where there are large addressable market opportunities, among other factors. Our clinical pipeline is focused on two therapeutic areas: Medical Dermatology and Respiratory. In Medical Dermatology we are developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. CXCL10 has been shown to play a key role in the disease, and neutralization of CXCL10 has been demonstrated to both prevent and reverse depigmentation in animal models. To date, EB06 has demonstrated a favorable safety and tolerability profile. We have received regulatory approval from Health Canada to conduct a Phase 2 proof of concept study of EB06 in patients with moderate-to-severe nonsegmental vitiligo and we are in discussions with the U.S. Food and Drug Administration (FDA) for the same study. Our medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase 3-ready asset developed for use as a potential therapy for moderate-to-severe chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. This asset is at the partnering stage. Our most advanced Respiratory drug candidate is EB05 (paridiprubart). Paridiprubart represents a new class of emerging therapies called Host-Directed Therapeutics (HDTs) that are designed to modulate the body's own immune response when confronted with infectious diseases or even chemical agents. EB05 is currently being evaluated in a U.S. government-funded platform study in

View Full Filing

View this 10-K filing on SEC EDGAR